2019
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal Of Cardiac Failure 2019, 26: 270-275. PMID: 31857197, PMCID: PMC7078046, DOI: 10.1016/j.cardfail.2019.12.001.Peer-Reviewed Original ResearchConceptsLA reservoir strainLA myopathyHeart failureNT-proBNPEjection fractionLA reservoirReservoir strainLA strainN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAtrial mechanical dysfunctionEjection Fraction trialLA contractile strainLower LA reservoirJugular venous pressurePoor clinical outcomePhosphodiesterase-5 inhibitionAssociation of LAAtrial myopathyBaseline echocardiogramRELAX trialNeurohormonal activationExercise capacityVenous pressureClinical outcomesRenal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function
Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED, Felker GM, Anstrom KK, Mahoney DD, Bart BA, Tang WHW, Velazquez EJ, Testani JM. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation Heart Failure 2019, 12: e005552. PMID: 31163974, PMCID: PMC6585463, DOI: 10.1161/circheartfailure.118.005552.Peer-Reviewed Original ResearchConceptsRenal tubular injury biomarkersTubular injury biomarkersHeart failure patientsAcute decompensated heart failure patientsDecompensated heart failure patientsTubular injury markersInjury biomarkersFailure patientsRenal functionInjury markersAcute decompensated heart failureVolume removalCARRESS-HF trialRenal function recoveryDecompensated heart failureRenal tubular injuryRenal effectsSerum creatinineTubular injuryBiomarker substudyHeart failurePharmacological therapyClinical outcomesFunction recoveryHigh incidenceCardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. European Heart Journal 2019, 40: 3345-3352. PMID: 31093657, PMCID: PMC6801941, DOI: 10.1093/eurheartj/ehz240.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanAcute decompensated HFAcute decompensated heart failureSoluble ST2Decompensated heart failureHeart failureUrinary cGMPMyocardial stressHigh-sensitivity cardiac troponinCyclic guanosine 3'5PIONEER-HF trialDouble-blind trialReduced ejection fractionMultivariable-adjusted analysesGreater reductionNatriuretic peptide receptorPIONEER-HFCardiovascular deathCardiac afterloadHaemodynamic stabilizationEjection fractionHospitalized patientsMyocardial injuryCardiovascular biomarkersTreatment groups
2018
Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension
Siddiqui I, Rajagopal S, Brucker A, Chiswell K, Christopher B, Alenezi F, Mandawat A, Rivera D, Arges K, Tapson V, Kisslo J, Velazquez E, Douglas PS, Samad Z. Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension. The American Journal Of Cardiology 2018, 122: 872-878. PMID: 30093068, PMCID: PMC6280670, DOI: 10.1016/j.amjcard.2018.05.019.Peer-Reviewed Original ResearchConceptsPrecapillary pulmonary hypertensionRV global longitudinal strainPulmonary hypertensionEchocardiographic parametersHard outcomesPulmonary arterial hypertension medicationsClass III symptomsREVEAL risk scoreRight heart functionCohort of patientsCumulative incidence rateCurrent clinical guidelinesGlobal longitudinal strainEchocardiographic predictorsHypertension medicationsNT-proBNPTransthoracic echocardiographyWalk distanceUnivariable analysisMean ageClinical guidelinesIncidence rateMultivariable modelSurrogate outcomesRisk score
2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2016
Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure
Hunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, Ilkayeva O, Stevens RD, Bain JR, Muehlbauer MJ, Newgard CB, Felker GM, Hernandez AF, Velazquez EJ, Kraus WE, Shah SH. Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. Journal Of The American Heart Association 2016, 5: e003190. PMID: 27473038, PMCID: PMC5015273, DOI: 10.1161/jaha.115.003190.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionReduced ejection fractionEjection fractionHF controlsHFpEF casesHeart failureMetabolic impairmentVersus Reduced Ejection FractionHistory of HFNormal diastolic functionNovel circulating biomarkersClinical heart failureVentricular ejection fractionDiastolic dysfunction gradeHeart failure pathogenesisStrict inclusion criteriaFatty acid oxidationLVEF spectrumCardiac catheterizationDiastolic functionHF diagnosisSequential patientsMetabolic abnormalitiesInsulin resistanceCirculating BiomarkersMarkers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya
Bloomfield GS, DeLong AK, Akwanalo CO, Hogan JW, Carter EJ, Aswa DF, Binanay C, Koech M, Kimaiyo S, Velazquez EJ. Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. Global Heart 2016, 11: 97-107. PMID: 27102027, PMCID: PMC4843836, DOI: 10.1016/j.gheart.2015.12.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexAtherosclerosisBiomarkersCardiomyopathy, DilatedCase-Control StudiesDyslipidemiasEchocardiographyElectrocardiographyFemaleGuideline AdherenceHeart FailureHumansHypertensionKenyaLogistic ModelsMaleMiddle AgedMyocardial IschemiaOdds RatioPractice Guidelines as TopicRisk FactorsRural PopulationConceptsAnkle-brachial indexAtherosclerotic risk factorsIschemic heart failureHeart failureCase-control studyWall motion abnormalitiesRisk factorsMotion abnormalitiesAdult heart failure patientsHuman immunodeficiency virus (HIV) infectionA Case-Control StudyContribution of atherosclerosisImmunodeficiency virus infectionMarker of atherosclerosisHeart failure patientsMultivariable logistic regressionPhysical examination findingsConfidence intervalsRural KenyaIschemic patternLipid testingClinical characteristicsFailure patientsMost patientsExamination findings
2015
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact
Buggey J, Mentz RJ, DeVore AD, Velazquez EJ. Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact. Journal Of Cardiac Failure 2015, 21: 741-750. PMID: 26209000, DOI: 10.1016/j.cardfail.2015.07.008.Peer-Reviewed Original ResearchConceptsHeart failureNeprilysin inhibitionClinical dataClinical impactAngiotensin receptor-neprilysin inhibitionRate of angioedemaAngiotensin receptor blockersEnzyme inhibitor enalaprilMechanistic actionImproved safety profileSignificant reductionARNi LCZ696Aldosterone systemHF patientsHF severityReceptor blockersCardiorenal effectsNeprilysin inhibitorHF populationNatriuretic peptideSafety profileACE inhibitionSurrogate markerClinical trialsCommon syndrome
2013
Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation Heart Failure 2013, 6: 461-472. PMID: 23584092, PMCID: PMC3905743, DOI: 10.1161/circheartfailure.112.000185.Peer-Reviewed Original ResearchConceptsCoronary artery bypassPrimary end pointCoronary artery diseaseIndependent prognostic informationArtery bypassMultivariable analysisPrognostic informationSTNFR-1Artery diseaseClinical factorsPlasma levelsUnivariate analysisIschemic Heart Failure (STICH) trialEnd pointSoluble tumor necrosisHeart Failure TrialLeft ventricular reconstructionPrimary outcome variableNet reclassification improvementAbility of biomarkersSubstudy patientsVentricular dysfunctionCardiac hospitalizationBiomarker substudyHeart failure
2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney International 2011, 81: 568-576. PMID: 22189843, DOI: 10.1038/ki.2011.417.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBiomarkersBlack or African AmericanBlood PressureCalcium Channel BlockersCardiovascular DiseasesChi-Square DistributionCreatinineDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionIncidenceKaplan-Meier EstimateKidneyKidney Failure, ChronicMaleMiddle AgedMultivariate AnalysisProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesUp-RegulationConceptsHigh cardiovascular riskNon-black patientsSerum creatinineCardiovascular riskEnd-stage renal diseaseBlood pressure goalsHypertensive black patientsAcute hemodynamic effectsEffective antihypertensive treatmentKidney disease progressionGlomerular filtration rateDouble-blinded mannerEvent-driven trialDisease end pointsACCOMPLISH trialAntihypertensive treatmentRenal outcomesEGFR lossHemodynamic effectsRenal diseaseBlack patientsBlack ethnicityFiltration rateDisease progressionPatients
2008
Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis